# homozygous familial hypercholesterolemia FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/homozygous-familial-hypercholesterolemia

> 4 upcoming FDA catalysts in homozygous familial hypercholesterolemia: zodasiran (ARWR) on Aug to Nov 2027 (topline data readout); zodasiran (ARWR) on August 2027 (primary completion); zodasiran (ARWR) on July 2028 (primary completion); zodasiran (ARWR) on Jul to Oct 2028 (topline data readout).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Sep 2025 | [Evkeeza® (evinacumab) FDA approval](https://sec-api.dev/pdufa/evinacumab) | REGN | homozygous familial hypercholesterolemia | completed, approved | "•In September 2025, the FDA approved Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH), extending the already approved indication to include children from age 1 to less than 5 years old." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/872589/000087258925000026/exhibit991q32025.htm)) |
| Aug to Nov 2027 | [Zodasiran topline data readout](https://sec-api.dev/pdufa/zodasiran) | ARWR | Homozygous Familial Hypercholesterolemia | scheduled | "NCT07037771 (A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-20 (ESTIMATED); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07037771)) |
| August 2027 | [Zodasiran primary completion](https://sec-api.dev/pdufa/zodasiran) | ARWR | Homozygous Familial Hypercholesterolemia | scheduled | "NCT07037771 (A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-08-20 (ESTIMATED); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07037771)) |
| July 2028 | [Zodasiran primary completion](https://sec-api.dev/pdufa/zodasiran) | ARWR | Homozygous Familial Hypercholesterolemia | scheduled | "NCT07473843 (Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07473843)) |
| Jul to Oct 2028 | [Zodasiran topline data readout](https://sec-api.dev/pdufa/zodasiran) | ARWR | Homozygous Familial Hypercholesterolemia | scheduled | "NCT07473843 (Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Arrowhead Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07473843)) |

## Drugs

- [Evkeeza® (evinacumab)](https://sec-api.dev/pdufa/evinacumab) (REGN)
- [Zodasiran](https://sec-api.dev/pdufa/zodasiran) (ARWR)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/homozygous-familial-hypercholesterolemia.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "homozygous familial hypercholesterolemia FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/homozygous-familial-hypercholesterolemia

```bibtex
@misc{secapidev_indications_homozygous_familial_hypercholesterolemia_20261116,
  title        = {homozygous familial hypercholesterolemia FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/homozygous-familial-hypercholesterolemia}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_homozygous_familial_hypercholesterolemia_20261116","title":"homozygous familial hypercholesterolemia FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/homozygous-familial-hypercholesterolemia","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
